The stock declined by 4.71 per cent to settle at Rs 686.90 on BSE. During the day, it went down by 5.61 per cent to Rs 680.35.
On NSE, shares of the company dipped 4.62 per cent to close at Rs 687.90.
Also Read
Drug firm Divi's Laboratories on Saturday reported 41.50 per cent dip in standalone net profit at Rs 176.54 crore for the first quarter ended June 30, impacted by USFDA alert for a unit at its Visakhapatnam facility.
The company had posted a net profit of Rs 301.81 crore for the corresponding period of previous fiscal.
Standalone total revenue from operations stood at Rs 850.88 crore for the quarter under review. It stood at Rs 1,033.50 crore for the same period a year ago.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)